FeesSafety
Pluang+

Petra Diamonds shares drop 26% as audit delay triggers likely trading suspension

Market News
23 Oct 2026
Proactive Investors
View Source
Bearish
Petra Diamonds shares drop 26% as audit delay triggers likely trading suspension

Petra Diamonds shares fell 26% after the company announced it will miss the deadline to publish its annual financial results for the year ending June 30, 2026. The delay is due to outstanding audit procedures and reviews needed to finalize the consolidated accounts. As a result, Petra expects its shares to be suspended from trading starting November 2 until the audit and report publication are complete. The timing for resuming trading and the annual general meeting is uncertain, but the company is working closely with auditors to resolve the issue promptly.

Petra Diamonds shares faced a sharp drop amid audit delays. For readers following the Basic Materials sector, here is Pluang's market snapshot as of Oct 23, 2026 17:11 WIB: out of 83 priced US stocks, 28 rose and 51 fell. Notably, Newmont Corporation (NEM) traded at USD 111.50 with a 2.29% decline and a typical hold time of 59 days, while Teck Resources (TECK) rose 1.87% to USD 60.00 despite 100% sell order activity and a shorter hold time of 17 days. Century Aluminum (CENX) dropped 1.53% to USD 32.15 with a very brief hold time of 3 days.

More News

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...

Market News
Bullish
20 minutes ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
1 hour ago
Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
1 hour ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
1 hour ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App